Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Alumis Announces $259M Series C Financing

2024-03-06
SOUTH SAN FRANCISCO, CA, Alumis Inc., a clinical-stage biopharmaceutical company, announced an upsized $259M Series C financing.
Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, announced an upsized $259M Series C financing.

The financing was co-led by existing investor, Foresite Capital, and new investors, Samsara BioCapital and venBio Partners, with additional participation from new investors Cormorant Asset Management, SR One, Lilly Asia Ventures, Nextech, Ally Bridge Group, HBM Healthcare Investments, Omega Funds, Piper Heartland Healthcare and existing investors AyurMaya, an affiliate of Matrix Capital Management and a U.S.-based healthcare-focused fund.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors